Holen Sie sich die Stockscreener-App
7.72
15.26%
-1.39
Handel nachbörslich:
7.41
-0.31
-4.02%
Schlusskurs vom Vortag:
$9.11
Offen:
$8.92
24-Stunden-Volumen:
411.92K
Relative Volume:
3.31
Marktkapitalisierung:
$850.94M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
82.57
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
-16.18%
1M Leistung:
-33.45%
6M Leistung:
-38.44%
1J Leistung:
-55.84%
1-Tages-Spanne:
$7.00
$9.1075
1-Wochen-Bereich:
$7.00
$9.50
52-Wochen-Spanne:
$7.00
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(619) 949-3681
Adresse
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Vergleichen Sie GYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.72 | 850.94M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges - Investing.com UK
Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury - MarketScreener
Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks
Major Breakthrough: Gyre's Cancer Drug Trial Targets 25% of Radiation Therapy Patients - Stock Titan
Bank of New York Mellon Corp Has $168,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance
Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - Stock Titan
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why - Defense World
Gyre therapeutics president Ma Songjiang sells $40,440 in stock By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells $40,440 in stock - Investing.com India
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings - TipRanks
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock - Investing.com
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Gyre Therapeutics Inc (GYRE) Q4 2024 Earnings: Revenue Surpasses Estimates at $27.9M, EPS Misses at $0.00 - GuruFocus.com
Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday - Defense World
Decoding Gyre Therapeutics Inc (GYRE): A Strategic SWOT Insight - GuruFocus
Gyre Therapeutics offers weak 2025 revenue guidance - Investing.com India
Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com - Investing.com Canada
Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases -March 17, 2025 at 04:52 pm EDT - Marketscreener.com
(GYRE) Gyre Therapeutics Sees 2025 Revenue Range $118M$128M -March 17, 2025 at 04:18 pm EDT - Marketscreener.com
FY2024 Earnings Forecast for GYRE Issued By Noble Financial - Defense World
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock By Investing.com - Investing.com Canada
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock - Investing.com India
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Exploring High Growth Tech Stocks In The US March 2025 - Simply Wall St
Gyre therapeutics president Ma Songjiang sells $40,776 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial - Defense World
Gyre therapeutics president Ma Songjiang sells $40,776 in stock - Investing.com
Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target - Marketscreener.com
Gyre Therapeutics initiated with an Outperform at Noble Capital - TipRanks
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Still a Buy? - Defense World
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock - Investing.com India
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Ma Songjiang sells $44,180 in stock - Investing.com
Gyre Therapeutics president Ma Songjiang sells $44,180 in stock By Investing.com - Investing.com UK
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
Gyre Therapeutics president Ma Songjiang sells $45,480 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Ma Songjiang sells $45,480 in stock - Investing.com India
Public companies in Gyre Therapeutics, Inc. (NASDAQ:GYRE) are its biggest bettors, and their bets paid off as stock gained 10.0% last week - Simply Wall St
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):